1. Home
  2. IMUX
  3. IMUX News

Latest Immunic Inc. (IMUX) News on July 30, 2025

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
IMUX

PR Newswire

a month ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

IMUX

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 06/06/2025

IMUX

MT Newswires

2 months ago

Immunic Completes Enrollment in 2 Phase 3 Studies in Relapsing Multiple Sclerosis

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
IMUX

PR Newswire

2 months ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
IMUX

PR Newswire

2 months ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic to Participate in Investor, Scientific and Industry Conferences in June
IMUX

PR Newswire

2 months ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

IMUX

MT Newswires

2 months ago

Immunic Tumbles After Pricing $65 Million Offering of Warrants

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
IMUX

PR Newswire

2 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

IMUX

MT Newswires

2 months ago

Immunic Begins Underwritten Public Offering

Immunic, Inc. Announces Proposed Public Offering
IMUX

PR Newswire

2 months ago

Immunic, Inc. Announces Proposed Public Offering

IMUX

MT Newswires

2 months ago

B. Riley Cuts Price Target on Immunic to $5 From $6, Keeps Buy Rating

IMUX

Associated Press Finance

2 months ago

Immunic: Q1 Earnings Snapshot

Immunic to Participate in Scientific and Industry Conferences in May
IMUX

PR Newswire

3 months ago

Immunic to Participate in Scientific and Industry Conferences in May

Immunic presses ahead with MS drug despite Phase II endpoint miss
IMUX

Clinical Trials Arena

3 months ago

Immunic presses ahead with MS drug despite Phase II endpoint miss

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
IMUX

PR Newswire

3 months ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

One Immunic Insider Raised Their Stake In The Previous Year
IMUX

Simply Wall St.

3 months ago

One Immunic Insider Raised Their Stake In The Previous Year

IMUX

MT Newswires

4 months ago

Immunic Raises $5.1 Million From Direct Stock Offering

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
IMUX

PR Newswire

4 months ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
IMUX

PR Newswire

4 months ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. to Participate in Scientific and Industry Conferences in April
IMUX

PR Newswire

4 months ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky
IMUX

Simply Wall St.

4 months ago

Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky

IMUX

MT Newswires

4 months ago

William Blair Initiates Immunic at Outperform With $6.80 Price Target

Immunic to Participate in Scientific and Investor Conferences in March
IMUX

PR Newswire

5 months ago

Immunic to Participate in Scientific and Investor Conferences in March

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
IMUX

PR Newswire

5 months ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week
IMUX

Simply Wall St.

5 months ago

Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
IMUX

PR Newswire

5 months ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Immunic to Participate in Investor and Scientific Conferences in February
IMUX

PR Newswire

6 months ago

Immunic to Participate in Investor and Scientific Conferences in February

Immunic Highlights 2024 Accomplishments and Upcoming Milestones
IMUX

PR Newswire

7 months ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
IMUX

ACCESSWIRE

8 months ago

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

Immunic, Inc. to Participate in Investor Conference in December
IMUX

PR Newswire

8 months ago

Immunic, Inc. to Participate in Investor Conference in December

Insider Buys Additional US$100k In Immunic Stock
IMUX

Simply Wall St.

8 months ago

Insider Buys Additional US$100k In Immunic Stock

Immunic announces publication of IMU-856 data
IMUX

TipRanks

9 months ago

Immunic announces publication of IMU-856 data

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
IMUX

PR Newswire

9 months ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges
IMUX

GuruFocus.com

9 months ago

Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges

IMUX

Associated Press Finance

9 months ago

Immunic: Q3 Earnings Snapshot

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
IMUX

PR Newswire

9 months ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
IMUX

PR Newswire

9 months ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Immunic to Participate in Industry, Scientific and Investor Conferences in November
IMUX

PR Newswire

9 months ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

IMUX

MT Newswires

9 months ago

Immunic Shares Advance on Positive Outcome From Interim Analysis of Potential MS Treatment

IMUX

MT Newswires

9 months ago

Top Premarket Gainers

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
IMUX

PR Newswire

9 months ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully
IMUX

Simply Wall St.

9 months ago

We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully

IMUX

MT Newswires

10 months ago

Top Premarket Gainers

Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ...
IMUX

GuruFocus.com

10 months ago

Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ...

IMUX

MT Newswires

10 months ago

Immunic Says Initial Phase 2 Data Back Vidofludimus Calcium's Potential in Multiple Sclerosis

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
IMUX

PR Newswire

10 months ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Owning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX),
IMUX

Simply Wall St.

a year ago

Owning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX),

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
IMUX

PR Newswire

a year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
IMUX

PR Newswire

a year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

IMUX

MT Newswires

a year ago

B. Riley Securities Initiates Immunic at Buy With $6 Price Target

IMUX

Associated Press Finance

a year ago

Immunic: Q2 Earnings Snapshot

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
IMUX

PR Newswire

a year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
IMUX

PR Newswire

a year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
IMUX

PR Newswire

a year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

IMUX

MT Newswires

a year ago

Immunic Names Jason Tardio as COO, Werner Gladdines as Chief Development Officer

Immunic Appoints Jason Tardio as Chief Operating Officer and President
IMUX

PR Newswire

a year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
IMUX

Business Wire

a year ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
IMUX

GlobeNewswire

a year ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23
IMUX

GlobeNewswire

a year ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
IMUX

Simply Wall St.

a year ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May
IMUX

Reuters

a year ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'
IMUX

AFP

a year ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed
IMUX

PR Newswire

a year ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share
IMUX

GlobeNewswire

a year ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

When Will Immunic, Inc. (NASDAQ:IMUX) Breakeven?
IMUX

Simply Wall St.

a year ago

When Will Immunic, Inc. (NASDAQ:IMUX) Breakeven?

Immunic to Participate in Industry and Scientific Conferences in June
IMUX

PR Newswire

a year ago

Immunic to Participate in Industry and Scientific Conferences in June

Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript
IMUX

Insider Monkey

a year ago

Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript

We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully
IMUX

Simply Wall St.

a year ago

We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully

IMUX

Associated Press Finance

a year ago

Immunic: Q1 Earnings Snapshot

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
IMUX

PR Newswire

a year ago

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

Immunic to Participate in Investor and Scientific Conferences in May
IMUX

PR Newswire

a year ago

Immunic to Participate in Investor and Scientific Conferences in May

Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
IMUX

News Direct

a year ago

Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
IMUX

PR Newswire

a year ago

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
IMUX

PR Newswire

a year ago

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
IMUX

News Direct

a year ago

Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role

With 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investors
IMUX

Simply Wall St.

a year ago

With 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investors

Immunic to Host MS R&D Day and Participate in Investor Conferences in April
IMUX

PR Newswire

a year ago

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
IMUX

News Direct

a year ago

Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month

Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
IMUX

News Direct

a year ago

Immunic secures key patent, boosting MS drug exclusivity and global IP strategy

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
IMUX

PR Newswire

a year ago

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
IMUX

News Direct

a year ago

Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024

Immunic to Participate in Investor and Scientific Conferences in March
IMUX

PR Newswire

a year ago

Immunic to Participate in Investor and Scientific Conferences in March

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
IMUX

PR Newswire

a year ago

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

IMUX

GuruFocus.com

a year ago

Immunic Inc (IMUX) Reports Year-End 2023 Financial Results

Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript
IMUX

Insider Monkey

a year ago

Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript

Immunic reports successful 2023 and prepares for key 2025 milestones
IMUX

News Direct

a year ago

Immunic reports successful 2023 and prepares for key 2025 milestones

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
IMUX

PR Newswire

a year ago

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
IMUX

PR Newswire

a year ago

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update

Immunic to Participate in Investor and Scientific Conferences in February
IMUX

PR Newswire

a year ago

Immunic to Participate in Investor and Scientific Conferences in February

IMUX

Business Wire

2 years ago

Tillys Announces Leadership Transition

Freshpet, Tilly’s, and More Stocks See Action From Activist Investors
IMUX

Barrons.com

2 years ago

Freshpet, Tilly’s, and More Stocks See Action From Activist Investors

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
IMUX

GlobeNewswire

2 years ago

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

WeightWatchers Unveils “Beyond Hunger: Understanding Food Noise” Report Offering Insights Into the Experience of Ongoing, Intrusive Thoughts About Food
IMUX

GlobeNewswire

2 years ago

WeightWatchers Unveils “Beyond Hunger: Understanding Food Noise” Report Offering Insights Into the Experience of Ongoing, Intrusive Thoughts About Food

IMUX

GlobeNewswire

2 years ago

K. Hovnanian®️ Introduces Salerno Reserve, a New LOOKS Community in Stuart, FL

Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
IMUX

GlobeNewswire

2 years ago

Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

IMUX

Business Wire

2 years ago

Solo Brands Announces Leadership Change to Support Its Next Chapter of Growth

Is Syntec Optics Holdings, Inc.'s (NASDAQ:OPTX) 3.2% ROE Worse Than Average?
IMUX

Simply Wall St.

2 years ago

Is Syntec Optics Holdings, Inc.'s (NASDAQ:OPTX) 3.2% ROE Worse Than Average?

Immunic Highlights 2023 Accomplishments and Upcoming Milestones
IMUX

PR Newswire

2 years ago

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

Immunic, Inc. Announces Private Placement of up to $240 Million
IMUX

PR Newswire

2 years ago

Immunic, Inc. Announces Private Placement of up to $240 Million

IMUX

Business Wire

2 years ago

GAN Announces Launch of GAN Sports with Red Rock Resorts, Inc. under the STN Sports Brand

Share on Social Networks: